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SIRS, Biological therapies with antitumour necrosis fac-
tor-a drugs, including inﬂiximab, are now one of the
popular therapies in the treatment of inﬂammatory
bowel diseases and other diseases related to dysregulated
immunity.1, 2 Despite their effectiveness in control of
exacerbations and maintaining remission of these dis-
eases, this class of drugs may have serious side effects
including death.3–5 One of the major recommendations
since introduction of inﬂiximab, the ﬁrst of these drugs
to be commercially available, was slow infusion to avoid
side effects. Neef et al. in their article have claimed that
rapid infusion of inﬂiximab is not associated with more
side effects compared with standard infusion rate.6
As they have mentioned, this could not be generalised
to every patient especially those who are naïve to this
therapy. After several doses of infusion, patients usually
develop antibodies to this chimeric protein. These anti-
bodies could be neutralising or nonneutralising and
accordingly could have different effects on occurrence of
anaphylactic and other types of acute infusion reactions,
as well as the efﬁcacy of drug.7–9
I want to emphasise that the work of Neef et al.
should not lead to a change in infusion rates for inﬂix-
imab, especially in naïve patients.
ACKNOWLEDGEMENT
Declaration of personal and funding interests: None.
REFERENCES
1. Rosman Z, Shoenfeld Y, Zandman-Goddard G. Biologic therapy
for autoimmune diseases: an update. BMC Med 2013; 11: 88.
2. Denmark VK, Mayer L. Current status of monoclonal antibody
therapy for the treatment of inﬂammatory bowel disease: an
update. Expert Rev Clin Immunol 2013; 9: 77–92.
3. Lankarani KB. Mortality associated with inﬂiximab. J Clin
Gastroenterol 2001; 33: 255–6.
4. de’ Clari F, Salani I, Safwan E, Giannacco A. Sudden death in a
patient without heart failure after a single infusion of 200 mg
inﬂiximab: does TNF-alpha have protective effects on the failing
heart, or does inﬂiximab have direct harmful cardiovascular
effects? Circulation 2002; 105: E183.
5. Scheinfeld N. Off-label uses and side effects of inﬂiximab. J Drugs
Dermatol 2004; 3: 273–84.
6. Neef HC, Riebschleger MP, Adler J. Meta-analysis: rapid inﬂiximab
infusions are safe. Aliment Pharmacol Ther 2013; 38: 365–76.
7. Carrascosa JM. Immunogenicity in biologic therapy: implications
for dermatology. Actas Dermosiﬁliogr 2013; 104: 471–9.
8. Steenholdt C, Palarasah Y, Bendtzen K, et al. Pre-existing IgG
antibodies cross-reacting with the Fab region of inﬂiximab predict
efﬁcacy and safety of inﬂiximab therapy in inﬂammatory bowel
disease. Aliment Pharmacol Ther 2013; 37: 1172–83.
9. Nanda KS, Cheifetz AS, Moss AC. Impact of antibodies to
inﬂiximab on clinical outcomes and serum inﬂiximab levels in
patients with inﬂammatory bowel disease (IBD): a meta-analysis.
Am J Gastroenterol 2013; 108: 40–7.
Letter: rapid inﬂiximab infusion is not
always safe – authors’ reply
H. Neef & J. Adler
Division of Pediatric Gastroenterology, Department of Pediatrics and
Communicable Diseases, University of Michigan, Ann Arbor, MI, USA.
E-mail: jeradler@umich.edu
doi:10.1111/apt.12455
SIRS; We thank Lankarani for the letter in response to
our meta-analysis.1, 2 Although inﬂiximab may occasion-
ally result in serious side effects, including death, the
focus of our meta-analysis was to speciﬁcally examine
infusion-related adverse effects of inﬂiximab. In this
regard, our data demonstrated that rapid infusions are
not associated with greater risk of infusion reaction. We
speciﬁcally addressed the risk of serious infusion re-
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actions (Figure S5) and delayed infusion reactions
(Figure S6), which were either the same or decreased in
patients receiving rapid inﬂiximab infusions.
We acknowledge that the rate of infusion could inﬂu-
ence adverse effects associated with inﬂiximab other than
that of infusion reactions. It should be noted that none
of the studies included in our meta-analysis identiﬁed a
death secondary to infusion reaction with rapid inﬂix-
imab infusions. In one paper, there were two deaths
reported that were deemed to be unrelated to inﬂiximab
infusions (one due to tuberculosis).3
As noted, we appropriately concluded that rapid infu-
sion of inﬂiximab is not associated with increased rate of
infusion reaction compared with standard infusions in
patients that have previously tolerated at least three stan-
dard rate infusions. Although we do not conclude that
inﬂiximab infusions are always safe, we do conclude that
the evidence demonstrates that rapid infusions are as
safe as standard infusions with regard to risk of infusion
reactions in this inﬂiximab-experienced population. We
do agree that there is insufﬁcient evidence to support
initiation of rapid inﬂiximab infusions in inﬂix-
imab-naïve patients.
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